GO
Loading...

Enter multiple symbols separated by commas

AstraZeneca PLC

More

  • CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...

  • *Roche, AstraZeneca gain on positive updates. LONDON, June 1- European shares held steady at the start of the month on Monday, with a rally in some drug stocks on the back of positive company updates offset by lingering concerns over Greece's debt situation and weaker commodity stocks. Drugmakers Roche and AstraZeneca, up 2.2 percent and 1 percent respectively,...

  • After BMY's drop, cancer drug stocks set to move? Monday, 1 Jun 2015 | 5:00 AM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.

  • LONDON, June 1- European shares kicked off June on a positive note on Monday, helped by a rise in pharma stocks, although main indexes were still stuck in their recent range as uncertainty persisted over Greece's future. Athens and its euro zone and International Monetary Fund creditors have been locked in talks for months on a cash-for-reforms agreement.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...

  • These biotechs may surge on drug news: Expert Friday, 29 May 2015 | 3:31 PM ET
    Lab science research

    Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.

  • Here's why Puma, Clovis shares are poised to move Friday, 29 May 2015 | 2:49 PM ET
    Attendees walk through the lobby at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. (File Photo).

    It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.

  • New class of drugs shows promise for cancer fight Friday, 29 May 2015 | 2:18 PM ET

    A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • Early movers: TWC, AAPL, CTRP, CRM, GM & more Tuesday, 26 May 2015 | 7:54 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • LONDON, May 26- AstraZeneca's hopes of topping $45 billion in revenue by 2023 have been dealt a blow by a problem with an experimental psoriasis drug that the drugmaker had viewed as a potential billion-dollar plus seller. AstraZeneca and Amgen have been sharing development of brodalumab since 2012 as a treatment for psoriasis, psoriatic arthritis and axial...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop a psoriasis drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen said.

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in the subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 22- Amgen Inc said it will terminate a collaboration with AstraZeneca Plc to develop an inflammation drug after it observed suicidal thoughts in subjects of a trial. AstraZeneca could decide on the development and marketing of the drug for all territories, except for Japan and certain Asian territories, where Kyowa Hakko Kirin has the rights to it, Amgen...

  • May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drugs sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may cause dangerously high levels of blood acids that could require hospitalization. The FDA said its Adverse Event Reporting System database...

  • U.S. FDA warns on newer class of type 2 diabetes drugs Friday, 15 May 2015 | 11:06 AM ET

    May 15- The U.S. Food and Drug Administration on Friday warned that a widely used newer class of type 2 diabetes drug sold by AstraZeneca, Johnson& Johnson and Eli Lilly in partnership with Boehringer Ingleheim may a cause dangerously high levels of blood acids that could require hospitalization. They include AstraZeneca's Farxiga, J&J's Invokana and...

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...

  • A hot biotech that may be the next Genentech Tuesday, 12 May 2015 | 7:00 AM ET
    Biotech

    This company has raised $1 billion to develop the Holy Grail in drugs: Have the body's own cells churn out proteins to fight disease.

  • Disruptor 50: No.1 Moderna Therapeutics Tuesday, 12 May 2015 | 7:00 AM ET
    Stéphane Bancel, president and founding CEO, Moderna Therapeutics

    A biotech company that helps the human body make the medicine it needs to cure a range of disease—from cancer to diabetes.